Gluvic Z, Obradovic M, Lackovic M, Samardzic V, Tica Jevtic J, Essack M, Bajic VB, Isenovic ER. HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review.
J Clin Pharm Ther 2020;
45:379-383. [PMID:
31736110 PMCID:
PMC7384187 DOI:
10.1111/jcpt.13073]
[Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 10/03/2019] [Accepted: 10/22/2019] [Indexed: 02/05/2023]
Abstract
WHAT IS KNOWN AND OBJECTIVE
The HbA1C marker used in assessing diabetes control quality is not sufficient in diabetes patients with thalassaemia.
CASE DESCRIPTION
A male diabetic patient with thalassaemia was hospitalized due to distal neuropathic pain, right toe trophic ulcer, unacceptable five-point glycaemic profile and recommended HbA1C value. After simultaneously initiated insulin therapy and management of ulcer by hyperbaric oxygen, the patient showed improved glycaemic control and ulcer healing, which led to the patient's discharge.
WHAT IS NEW AND CONCLUSION
In thalassaemia and haemoglobinopathies, due to discrepancies in the five-point glycaemic profile and HbA1C values, it is necessary to measure HbA1C with a different method or to determine HbA1C and fructosamine simultaneously.
Collapse